Actively Recruiting

Age: 40Years - 80Years
MALE
NCT07417449

Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP

Led by Ankara City Hospital Bilkent · Updated on 2026-04-06

1000

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study aims to investigate the effects of long-term dutasteride use (a 5-alpha reductase inhibitor) on surgical outcomes in patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP) for benign prostatic hyperplasia (BPH). While some studies suggest that short-term use of these medications can reduce bleeding during surgery, there is limited data on the impact of chronic, long-term use (at least 6 months) specifically during the HoLEP procedure. The researchers will retrospectively analyze patient records to compare two groups: those who used dutasteride for 6 months or longer before surgery, and those who did not use any 5-alpha reductase inhibitors. The primary focus is to determine whether long-term dutasteride treatment leads to a significant difference in surgical bleeding (measured by hemoglobin drop), operation time, and the efficiency of removing prostate tissue (morcellation). The findings will help surgeons better understand how preoperative medication history influences the technical aspects of HoLEP surgery.

CONDITIONS

Official Title

Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP

Who Can Participate

Age: 40Years - 80Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male patients aged 40 to 80 years
  • Diagnosed with symptomatic Benign Prostatic Hyperplasia (BPH) and scheduled for elective Holmium Laser Enucleation of the Prostate (HoLEP)
  • For the study group: Continuous use of Dutasteride (0.5 mg/day) for at least 6 months immediately before surgery
  • For the control group: No 5-alpha reductase inhibitor use within the last 12 months
  • Complete medical records available in the Hospital Information Management System (HBYS)
Not Eligible

You will not qualify if you...

  • History of previous prostate surgery or pelvic radiotherapy
  • Diagnosis of prostate adenocarcinoma in pathology or scheduled biopsy for suspected prostate cancer before surgery
  • Incomplete data in hospital records, including missing operative notes, hemoglobin levels, or resected tissue weight

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ankara Bilkent City Hospital

Ankara, Universiteler, Turkey (Türkiye), 06800

Actively Recruiting

Loading map...

Research Team

Y

Yusuf Gökkurt, MD, Specialist

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP | DecenTrialz